The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis

The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis

  • Post category:Drug Updates
  • Reading time:9 mins read

Introduction

Invasive candidiasis (IC) continues to be a major cause of morbidity and mortality among hospitalised patients, particularly those admitted to intensive care units and individuals with compromised immune systems. Early diagnosis and timely initiation of appropriate antifungal therapy are critical for improving patient outcomes. However, the emergence of antifungal resistance, changing Candida species distribution and the increasing prevalence of multidrug-resistant pathogens have made treatment increasingly challenging.

Conventional antifungal agents, including azoles, echinocandins and polyenes, remain important in clinical practice. Nevertheless, resistance, drug toxicity, drug interactions and limitations in administration routes can complicate treatment, particularly in critically ill patients.

A review published in Infection and Drug Resistance in April 2026, titled The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis, by Anna Zubovskaia and Jose A. Vazquez, explores emerging antifungal agents that may expand the treatment options available for invasive candidiasis. The review examines their mechanisms of action, antifungal activity, resistance profiles and available clinical trial evidence.

Understanding Invasive Candidiasis and the Growing Challenge of Antifungal Resistance

Invasive candidiasis occurs when Candida species enter normally sterile body sites, potentially causing bloodstream infections and deep-seated infections. Candidemia, the presence of Candida in the bloodstream, is its most common presentation.

The majority of candidemia cases are healthcare-associated, with critically ill patients particularly vulnerable due to prolonged hospitalisation, invasive medical devices, exposure to broad-spectrum antibiotics and underlying conditions.

According to surveillance data cited in the review:

  • The incidence of candidemia in the United States was reported at 7.4 cases per 100,000 population.
  • The all-cause in-hospital mortality rate was approximately 32.8%.
  • Non-albicans Candida species account for up to two-thirds of candidemia cases in the United States.
  • Candida auris, an emerging multidrug-resistant fungal pathogen, has become a significant concern due to its ability to spread in healthcare settings and its resistance to multiple antifungal agents.

The changing epidemiology of Candida infections, combined with increasing antifungal resistance, highlights the need for new therapeutic approaches.

Emerging Antifungal Agents: What Does the Review Highlight?

The review discusses several antifungal agents in different stages of clinical development. Among these, ibrexafungerp, rezafungin and fosmanogepix have generated considerable interest due to their distinct mechanisms of action and potential applications in invasive candidiasis.

1. Ibrexafungerp: An Oral Antifungal with Activity Against Resistant Candida Species

Ibrexafungerp belongs to the triterpenoid class of antifungal agents. It works by inhibiting the 1,3-β-D-glucan synthase enzyme complex, disrupting fungal cell wall formation and ultimately leading to fungal cell death.

Unlike conventional echinocandins, ibrexafungerp has an oral formulation and demonstrates activity against several fluconazole-resistant and echinocandin-resistant Candida species.

Key characteristics:

  • Demonstrates activity against C. albicans, C. glabrata, C. tropicalis and C. auris.
  • Retains activity against several echinocandin-resistant Candida isolates due to differences in drug-binding interactions.
  • Exhibits activity against both planktonic Candida cells and biofilms.
  • Its oral formulation offers potential for step-down therapy following initial intravenous antifungal treatment.

Clinical evidence:

The CARES study evaluated oral ibrexafungerp in patients with C. auris candidemia and invasive candidiasis. The reported global success rate was 70% (21 out of 30 patients) in the intention-to-treat population.

Another study, the FURI trial, reported treatment success rates of 65.6% in the intention-to-treat population and 75.5% in the per-protocol population among participants with acute invasive candidiasis.

These findings suggest that ibrexafungerp may become a useful option for patients with difficult-to-treat Candida infections. However, further clinical evidence is required to establish its role in invasive candidiasis.

2. Rezafungin: A Long-Acting Echinocandin with Once-Weekly Dosing

Rezafungin is a second-generation echinocandin developed to improve pharmacokinetic properties while retaining the antifungal activity of its drug class.

It inhibits the 1,3-β-D-glucan synthase enzyme complex, preventing fungal cell wall formation. Its prolonged half-life allows once-weekly intravenous administration, offering a potential advantage over conventional echinocandins that generally require daily dosing.

Key characteristics:

  • Demonstrates activity against several Candida species, including C. albicans, C. glabrata and C. auris.
  • Has a prolonged half-life that supports once-weekly administration.
  • Demonstrates a favourable safety profile and limited clinically significant drug interactions.
  • Does not generally require dose adjustment in patients with renal impairment, including those receiving haemodialysis.
  • May offer advantages for outpatient parenteral antimicrobial therapy (OPAT).

Clinical evidence:

The Phase III ReSTORE trial compared rezafungin with caspofungin in patients with candidemia and invasive candidiasis.

The study included 199 patients. Global cure at Day 14 was achieved in 59% of patients receiving rezafungin compared with 61% receiving caspofungin.

Rezafungin met the study’s non-inferiority criteria for the primary endpoints, supporting its efficacy as a treatment option for candidemia and invasive candidiasis.

The review also highlights its potential role in outpatient treatment programmes, particularly because of its convenient weekly dosing schedule.

3. Fosmanogepix: A Novel Antifungal with a Distinct Mechanism of Action

Fosmanogepix is a prodrug that is converted into its active form, manogepix. It works through a novel mechanism by inhibiting the fungal Gwt1 protein, which plays an important role in the biosynthesis of glycosylphosphatidylinositol (GPI)-anchored proteins.

These proteins contribute to fungal cell wall integrity, adhesion and virulence. By disrupting their production and localisation, fosmanogepix interferes with fungal growth and survival.

Key characteristics:

  • Available in both intravenous and oral formulations in clinical development.
  • Demonstrates broad-spectrum activity against several Candida species, including C. glabrata and C. auris.
  • Shows activity against certain azole-resistant and echinocandin-resistant fungal isolates.
  • Demonstrates activity against several moulds, including Aspergillus and Fusarium species.
  • Has shown promising results in experimental models of invasive candidiasis, including central nervous system and ocular infections.

Clinical evidence:

A Phase II study evaluated fosmanogepix as a treatment for candidemia in patients with suspected or documented resistance to at least one systemic antifungal agent.

Treatment success at the end of treatment was achieved in 15 patients, representing 75% of the modified intention-to-treat population.

Another Phase II study evaluated its use in patients with C. auris candidemia and limited treatment options. Treatment success and Day 30 survival were both reported at 89% (8 out of 9 patients).

These findings indicate potential for fosmanogepix in treating difficult-to-manage invasive fungal infections. However, larger clinical trials are required to establish its efficacy and safety.

Other Antifungal Agents in Early Clinical Development

In addition to the three agents discussed above, the review highlights several other compounds and repurposed drugs that may contribute to the future management of invasive candidiasis.

1. Encochleated Amphotericin B (CAmB)

This is an oral formulation of amphotericin B in which the active compound is encapsulated within a lipid-based cochleate structure. This delivery system aims to improve drug stability and reduce the toxicity associated with conventional intravenous amphotericin B.

Preclinical studies have demonstrated antifungal activity against Candida infections. However, clinical evidence in patients with invasive candidiasis remains unavailable.

2. ATI2307 (T-2307)

ATI2307 is a novel arylamidine antifungal compound that targets fungal mitochondrial function by inhibiting respiratory chain enzyme complexes III and IV.

It has demonstrated activity against several fungal pathogens, including azole-resistant and echinocandin-resistant Candida isolates, as well as C. auris, in laboratory and animal studies.

Its potential clinical role in invasive candidiasis requires further investigation.

3. VT-1598

VT-1598 is a novel tetrazole-based antifungal candidate that selectively inhibits the fungal CYP51 enzyme, which is involved in ergosterol biosynthesis.

It has demonstrated activity against several Candida species, including fluconazole-resistant isolates, and has shown promising results in experimental models of C. auris infection.

Although early safety and pharmacokinetic findings are encouraging, human efficacy data in invasive candidiasis are not yet available.

4. BAL2062

BAL2062 is a novel antifungal compound with a mechanism of action that is not yet fully understood. Its uptake into fungal cells depends on the Sit1 transporter.

It has demonstrated activity against selected Candida species, particularly C. glabrata and C. kefyr, including certain drug-resistant isolates.

Its potential applications include targeted treatment of infections caused by these species, although further clinical research is needed.

5. Miltefosine

Originally developed as an antitumour agent and subsequently repurposed for the treatment of leishmaniasis, miltefosine has also demonstrated antifungal activity against several fungal pathogens.

Laboratory studies have shown activity against Candida species, including C. albicans, C. glabrata and C. auris. It has also demonstrated activity against fungal biofilms.

However, human studies evaluating its safety and efficacy in invasive candidiasis are yet to be conducted.

What Do These Developments Mean for the Future of Invasive Candidiasis Management?

The development of new antifungal agents represents an important step towards addressing the challenges associated with antifungal resistance and limited treatment options.

The agents discussed in the review offer different potential advantages:

  • New mechanisms of action: Fosmanogepix and ATI2307 target fungal pathways that differ from those targeted by conventional antifungal agents.
  • Activity against resistant pathogens: Ibrexafungerp and fosmanogepix have demonstrated activity against several resistant Candida isolates, including C. auris.
  • Improved treatment convenience: The once-weekly dosing schedule of rezafungin may support outpatient treatment and reduce the burden of prolonged hospital-based intravenous therapy.
  • Alternative administration routes: Oral formulations of ibrexafungerp and fosmanogepix may provide additional flexibility in treatment planning.
  • Potential for expanded antifungal coverage: Compounds in early development may help address infections caused by fungal pathogens with limited existing treatment options.

Despite these promising developments, the clinical utility of each agent will depend on further evidence from well-designed clinical trials, including evaluations of efficacy, safety, resistance development and appropriate patient selection.

Conclusion

Invasive candidiasis remains a significant healthcare challenge, particularly with the emergence of multidrug-resistant Candida species and the limitations of currently available antifungal therapies.

The review by Zubovskaia and Vazquez highlights several promising antifungal agents at different stages of clinical development. Ibrexafungerp, rezafungin and fosmanogepix have demonstrated encouraging clinical or pharmacological characteristics that may expand future treatment options. Other investigational compounds, including ATI2307, BAL2062 and encochleated amphotericin B, also represent potential areas of development.

While these agents offer new possibilities for managing difficult-to-treat fungal infections, additional clinical research is essential to determine their appropriate place in therapy.

Continued advances in antifungal drug development, alongside early diagnosis, appropriate antifungal selection and effective antifungal stewardship, will be important in improving outcomes for patients with invasive candidiasis.

Reference

Zubovskaia A, Vazquez JA. The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis. Infection and Drug Resistance. 2026;19:547511. DOI: https://doi.org/10.2147/IDR.S547511